Skip to main content
OpenTrials
Completed

NCT Number: NCT07598968

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers

This clinical trial is a two-arm, open-label, single-sequence, multiple oral dosings, cross-over design clinical trial to evaluate the safety and pharmacokinetic characteristics of HL1113-R1 and HL1113-R2 in healthy adult volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Diabete Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Central Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult subjects aged ≥19 years at the time of screening
  • Subjects with no clinically significant congenital or chronic diseases based on screening, and no clinically significant findings on internal medicine examination (including, if necessary, electroencephalogram [EEG], electrocardiogram [ECG], chest examination, upper gastrointestinal endoscopy, or gastrointestinal radiography)
  • etc.

Exclusion criteria

  • Subjects who have received medications known to markedly induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 30 days prior to the screening visit
  • Subjects who have received any medications that may affect the outcome of the study within 10 days prior to the screening visit
  • etc.

Treatment and study plan

Test group 1

Drug
  • Period 1: HL1113-R1, once daily, administered for 7 days
  • Period 2: HL1113-R1 + HL1113-R2 once daily, administered for 7 days

Test group 2

Drug
  • Period 1: HL1113-R2, once daily, administered for 5 days
  • Period 2: HL1113-R2 + HL1113-R1 once daily, administered for 7 days

Primary outcomes

  1. AUCτ,ss

    Time frame: a steady state after 5~7 days of repeated administration

Secondary outcomes

  1. Tmax,ss

    Time frame: a steady state after 5~7 days of repeated administration

Sponsors and collaborators

Lead sponsor

Hanlim Pharm. Co., Ltd.

Industry

Registry information

Official study title

A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 20, 2026
Registry last updated
May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.